Gamal Shaza, Elseasi Ahmad Mohamad Abbas, Sabry Nirmeen Ahmed, Farid Samar Farghali
Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
National Institute of Urology and Nephrology, Cairo, Egypt.
NPJ Digit Med. 2025 May 30;8(1):325. doi: 10.1038/s41746-025-01742-8.
Medication adherence is crucial for slowing chronic kidney disease (CKD) progression. A specially designed pharmacist-led mobile application, Kidney Health, was evaluated in a single-center, prospective, 3 months, randomized controlled trial (RCT) to assess its impact on medication adherence and efficacy in patients with CKD. 86 patients were randomly assigned to control group, who received standard of care, and app group, who in addition, had access to Kidney Health. The primary outcome was medication adherence measured by simplified medication adherence questionnaire (SMAQ). Other outcomes evaluated included kidney function, blood pressure, and random blood glucose (RBG). The app group showed a significant increase in adherent patients (P < 0.001) and decreased RBG (P = 0.047). Adherent patients increased (P = 0.002) and RBG decreased (P = 0.006) in app group compared to control group at the end of the study. Kidney Health has shown potential for encouraging patients with CKD to adhere to their medication and improving their clinical outcomes. Trial registration: clinicaltrials.gov with ID: NCT05168449, Date of registration: 12/2021 https://clinicaltrials.gov/study/NCT05168449 .
药物依从性对于延缓慢性肾脏病(CKD)进展至关重要。在一项单中心、前瞻性、为期3个月的随机对照试验(RCT)中,对一款专门设计的由药剂师主导的移动应用程序“肾脏健康”进行了评估,以评估其对CKD患者药物依从性和疗效的影响。86名患者被随机分配到接受标准治疗的对照组和另外还能使用“肾脏健康”应用程序的应用程序组。主要结局是通过简化药物依从性问卷(SMAQ)测量的药物依从性。评估的其他结局包括肾功能、血压和随机血糖(RBG)。应用程序组中依从性患者显著增加(P < 0.001),RBG降低(P = 0.047)。在研究结束时,与对照组相比,应用程序组中依从性患者增加(P = 0.002),RBG降低(P = 0.006)。“肾脏健康”已显示出鼓励CKD患者坚持用药并改善其临床结局的潜力。试验注册:clinicaltrials.gov,ID:NCT05168449,注册日期:2021年12月https://clinicaltrials.gov/study/NCT05168449 。